Abstract
Crescentic IgA nephropathy (IgAN) with concurrent myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCA) is rare. It may represent a subgroup of IgAN with a different response to standard treatment.
Original language | English |
---|---|
Pages (from-to) | 216-217 |
Number of pages | 2 |
Journal | Nephrology |
Volume | 27 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2022 |
Keywords
- crescentic IgA nephropathy
- ANCA-positive vasculitis
- rituximab
- MPO-ANCA
- cyclophosphamide